ASKA Pharmaceutical Holdings Co., Ltd. AI Stock Analysis
Want to see JP:4886 full AI Analyst Report?
ASKA Pharmaceutical Holdings Co., Ltd. (4886) AI Stock Analysis
ASKA Pharmaceutical Holdings Co., Ltd.
(TSE/TYO:4886)
The company's financial foundation is a significant strength, driven by a pristine balance sheet and a strong cash flow recovery. However, the stock is under considerable technical pressure, trading below all major moving averages with weak momentum indicators. The attractive valuation and healthy dividend yield provide a counterbalance, suggesting the bearish price action may present a value opportunity for long-term investors.
ASKA Pharmaceutical Holdings Co., Ltd. (4886) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 61.45B
- Dividend Yield
- 3.01%
- Average Volume (3M)
- 67.56K
- Price to Earnings (P/E)
- 11.8
- Beta (1Y)
- 0.40
- Revenue Growth
- ―
- EPS Growth
- 9.04%
- Country
- Japan
- Employees
- 1,611
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
ASKA Pharmaceutical Holdings Co., Ltd. Business Overview & Revenue Model
Company Description
ASKA Pharmaceutical Holdings Co.,Ltd. is a Japanese enterprise that operates through its subsidiaries in three primary areas: pharmaceuticals, animal healthcare, and hormone testing services. The company's pharmaceutical division is dedicated to the...
ASKA Pharmaceutical Holdings Co., Ltd. Financial Statement Overview
Summary
Strong financial health overall. The balance sheet is excellent with minimal debt (D/E 0.05) and growing equity. Cash flow rebounded impressively in FY2026 with healthy conversion. Revenue growth is steady, though margin volatility slightly tempers the score.
Income Statement
78PositiveBalance Sheet
92Very PositiveCash Flow
84Very Positive| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 71.50B | 71.13B | 64.14B | 62.84B | 60.46B | 56.61B |
| Gross Profit | 33.96B | 34.15B | 31.34B | 30.66B | 28.59B | 26.35B |
| EBITDA | 7.58B | 8.75B | 7.58B | 9.16B | 8.24B | 7.68B |
| Net Income | 5.21B | 5.42B | 5.10B | 7.54B | 4.24B | 4.29B |
Balance Sheet | ||||||
| Total Assets | 111.88B | 112.01B | 103.25B | 93.31B | 87.14B | 83.30B |
| Cash, Cash Equivalents and Short-Term Investments | 6.86B | 11.02B | 11.16B | 17.24B | 17.91B | 17.10B |
| Total Debt | 9.91B | 11.43B | 10.90B | 9.48B | 12.62B | 14.05B |
| Total Liabilities | 31.65B | 35.56B | 34.06B | 31.38B | 32.60B | 34.40B |
| Stockholders Equity | 73.36B | 69.99B | 65.31B | 61.93B | 54.53B | 48.89B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 3.75B | -475.00M | 166.00M | 2.89B | 2.26B |
| Operating Cash Flow | 0 | 6.30B | 2.48B | 1.49B | 3.35B | 2.84B |
| Investing Cash Flow | 0 | -5.75B | -6.12B | 1.71B | -1.13B | 6.74B |
| Financing Cash Flow | 0 | -818.00M | -2.96B | -3.94B | -1.82B | -3.00B |
ASKA Pharmaceutical Holdings Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4886, the sentiment is Positive. The current price of 2160.00 is above the 20-day moving average (MA) of 2041.95, above the 50-day MA of 2047.28, and below the 200-day MA of 2302.19, indicating a neutral trend. The MACD of 28.14 indicates Negative momentum. The RSI at 61.70 is Neutral, neither overbought nor oversold. The STOCH value of 91.13 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4886.
ASKA Pharmaceutical Holdings Co., Ltd. Peers Comparison
Overall Rating
- JP:488670Outperform
JP:455469Neutral
JP:453468Neutral
JP:457767Neutral
JP:452164.9Neutral
JP:456952Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:4886 | 70Outperform | JPY 58.28B | 11.79 | ― | 3.01% | ― | 9.04% |
| JP:4554 | 69Neutral | JPY 48.97B | 16.85 | 5.56% | 2.80% | 20.72% | -10.35% |
| JP:4534 | 68Neutral | JPY 114.00B | 11.03 | 7.68% | 2.46% | 15.85% | 60.55% |
| JP:4577 | 67Neutral | JPY 38.11B | 12.10 | ― | 3.04% | -2.83% | 65.69% |
| JP:4521 | 65Neutral | JPY 138.31B | 15.83 | 6.11% | 4.97% | 5.43% | 1167.62% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| JP:4569 | 52Neutral | JPY 56.64B | 159.76 | ― | 4.35% | -6.48% | -95.83% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4886 | ASKA Pharmaceutical Holdings Co., Ltd. | 2160.00 | 185.51 | 9.40% | |
| JP:4521 | Kaken Pharmaceutical Co | 3825.00 | 314.47 | 8.96% | |
| JP:4554 | Fuji Pharma Co., Ltd. | 1857.00 | 225.16 | 13.80% | |
| JP:4534 | Mochida Pharmaceutical Co., Ltd. | 3355.00 | 123.57 | 3.82% | |
| JP:4569 | KYORIN Pharmaceutical Co.,Ltd. | 1080.00 | -304.25 | -21.98% | |
| JP:4577 | Daito Pharmaceutical Co., Ltd. | 1317.00 | 97.66 | 8.01% |
ASKA Pharmaceutical Holdings Co., Ltd. Corporate Events
ASKA Pharmaceutical Reports Higher First-Half Revenue and Operating Profit
ASKA Pharmaceutical Holdings, a Japan-focused pharmaceutical company developing and marketing prescription medicines and healthcare products, reported first-half sales of ¥35.626 billion for the six months ended September 30, up 1.1% year on year. Op...
ASKA Pharmaceutical Holdings Reports Revenue and Profit Growth
ASKA Pharmaceutical Holdings reported consolidated revenue of ¥35.6 billion for the six months ended September 30, 2026, up 1.1% year over year, supported by solid performance in its domestic pharmaceutical and animal health businesses. Operating pro...
ASKA Gains Japanese Rights to Minghui’s TED Drug Candidate
ASKA Pharmaceutical has obtained exclusive rights in Japan to develop and commercialize MHB018A, a subcutaneous monoclonal antibody targeting IGF-1R for thyroid eye disease (TED). The agreement with China-based Minghui Pharmaceutical includes a US$11...
ASKA Completes Reduced Employee Incentive Share Disposal
ASKA Pharmaceutical Holdings completed payment for a treasury-share disposal under its restricted-stock incentive program for the Employee Stock Ownership Association on November 2, 2026.Following the finalization of participating members, the alloca...
ASKA Pharmaceutical Completes Treasury Share Disposal for Restricted Stock Compensation
ASKA Pharmaceutical Holdings has completed payment procedures for the disposal of 53,600 treasury shares as restricted share remuneration, following a July 13, 2026 board resolution. The ordinary shares were disposed at 2,259 yen per share, for a tot...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 06, 2026